Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:CHRS
- CUSIP: N/A
- Web: www.coherus.com
Capitalization:- Market Cap: $700.08 million
- Outstanding Shares: 51,288,000
Average Prices:- 50 Day Moving Avg: $15.97
- 200 Day Moving Avg: $21.13
- 52 Week Range: $12.85 - $31.98
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.46
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $177.91 million
- Price / Sales: 3.95
- Book Value: $1.52 per share
- Price / Book: 9.01
Profitability:- EBIDTA: ($120,850,000.00)
- Net Margins: -76.85%
- Return on Equity: -827.65%
- Return on Assets: -64.39%
Debt:- Debt-to-Equity Ratio: 1.31%
- Current Ratio: 4.40%
- Quick Ratio: 4.40%
Misc:- Average Volume: 857,351 shs.
- Beta: 4.41
- Short Ratio: 6.54
Frequently Asked Questions for Coherus BioSciences (NASDAQ:CHRS)
What is Coherus BioSciences' stock symbol?
Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."
How were Coherus BioSciences' earnings last quarter?
Coherus BioSciences, Inc. (NASDAQ:CHRS) posted its quarterly earnings data on Monday, May, 8th. The company reported ($1.54) earnings per share for the quarter, meeting the consensus estimate of ($1.54). The firm earned $0.16 million during the quarter. Coherus BioSciences had a negative net margin of 76.85% and a negative return on equity of 827.65%. View Coherus BioSciences' Earnings History.
Where is Coherus BioSciences' stock going? Where will Coherus BioSciences' stock price be in 2017?
9 brokerages have issued 1-year price targets for Coherus BioSciences' stock. Their forecasts range from $24.00 to $46.00. On average, they expect Coherus BioSciences' share price to reach $38.50 in the next twelve months. View Analyst Ratings for Coherus BioSciences.
What are analysts saying about Coherus BioSciences stock?
Here are some recent quotes from research analysts about Coherus BioSciences stock:
- 1. Maxim Group analysts commented, "Coherus announced that the company received a CRL (Complete Response Letter) regarding its BLA for CHS-1701 (Neulasta)." (6/12/2017)
- 2. Credit Suisse Group analysts commented, "We are raising our PT from $35 to $40 post 4Q16. We arrive at our PT by using a DCF analysis. Post the quarter, we continue to believe that upwards earnings revisions to levels not yet reflected in sell-side expectations should drive ACRS shares higher. We believe upwards consensus earnings revisions could come from: 1) Faster than expected uptake and higher than expected peak sales of A-101 for SK; 2) Commercialization of A-101 for common warts; and, 3) Free call options on ATI-50001, ATI-50002, and other early stage pipeline opportunities. Positives from the 4Q16 release that support our thesis: 1) In November of ’16, ACRS reported that two pivotal Phase 3 trials of its lead product candidate A-101 40% Topical Solution met all primary and secondary endpoints of each trial, achieving clinically and statistically significant clearance of seborrheic keratosis (SK) lesions. In February 2017, ACRS submitted a New Drug Application NDA for A-101 40% Topical Solution for the treatment of SK to the FDA. 2) During ’16 ACRS also reported positive data from a Phase 2 trial of A-101 45% Topical Solution for the treatment of common warts. 3) ACRS recently completed a Phase 1 clinical trial of ATI-50001, its investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis. And, 4) ACRS had cash and cash equivalents of $174.1MM as of 12/31/16." (3/16/2017)
- 3. According to Zacks Investment Research, "Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. " (2/16/2017)
Who are some of Coherus BioSciences' key competitors?
Some companies that are related to Coherus BioSciences include Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), Synergy Pharmaceuticals (SGYP), Aduro Biotech (ADRO), Omeros Corporation (OMER), Achaogen (AKAO), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Five Prime Therapeutics (FPRX), NeuroDerm (NDRM) and PTC Therapeutics (PTCT).
Who are Coherus BioSciences' key executives?
Coherus BioSciences' management team includes the folowing people:
- Dennis M. Lanfear, Chairman of the Board, President, Chief Executive Officer
- Jean-Frederic Viret Ph.D., Chief Financial Officer
- Peter K. Watler, Chief Technology Officer
- Alan C. Herman Ph.D., Chief Scientific Officer
- Barbara K. Finck M.D., Chief Medical Officer
- Mats Wahlstrom, Lead Independent Director
- Christos Richards, Director
- August J. Troendle M.D., Director
- James I. Healy M.D. Ph.D., Independent Director
- V. Bryan Lawlis Jr. Ph.D., Independent Director
Who owns Coherus BioSciences stock?
Coherus BioSciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Handelsbanken Fonder AB (0.11%). Company insiders that own Coherus BioSciences stock include Alan C Herman, Christos Richards, Dennis M Lanfear, Fmr Llc, Jean-Frederic Viret, Mats Wahlstrom and Peter K Watler. View Institutional Ownership Trends for Coherus BioSciences.
Who bought Coherus BioSciences stock? Who is buying Coherus BioSciences stock?
How do I buy Coherus BioSciences stock?
Shares of Coherus BioSciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Coherus BioSciences' stock price today?
One share of Coherus BioSciences stock can currently be purchased for approximately $13.70.
MarketBeat Community Rating for Coherus BioSciences (NASDAQ CHRS)MarketBeat's community ratings are surveys of what our community members think about Coherus BioSciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Coherus BioSciences (NASDAQ:CHRS)Earnings History by Quarter for Coherus BioSciences (NASDAQ CHRS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/8/2017 | Q1 2017 | ($1.54) | ($1.54) | | $0.16 million | View | Listen |  |
| 3/13/2017 | Q4 2016 | ($1.11) | ($1.71) | $10.00 million | $0.84 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($1.56) | $1.67 | $7.20 million | $162.80 million | View | Listen | |
| 8/9/2016 | Q2 | ($1.32) | ($1.72) | $6.87 million | $14.07 million | View | Listen | |
| 5/9/2016 | Q1 | ($1.42) | ($1.67) | | $12.36 million | View | Listen | |
| 2/29/2016 | Q4 | ($1.74) | ($1.35) | $8.63 million | $10.20 million | View | Listen | |
| 11/9/2015 | Q3 | | ($1.86) | $16.10 million | $7.20 million | View | Listen | |
| 8/10/2015 | Q215 | | ($1.56) | $488.15 million | $6.87 million | View | Listen | |
| 5/11/2015 | Q115 | | ($1.22) | $488.15 million | $5.81 million | View | Listen | |
| 3/23/2015 | Q414 | ($0.46) | ($1.47) | | $6.50 million | View | Listen | |
| 12/15/2014 | Q212 | | ($1.79) | | $16.10 million | View | N/A | |
| 3/27/2012 | | ($0.02) | ($0.06) | | | View | N/A | |
| 12/1/2011 | | ($0.09) | ($0.08) | | | View | N/A | |
| 9/1/2011 | | $0.01 | ($0.01) | | | View | N/A | |
| 6/2/2011 | | $0.12 | $0.17 | | | View | N/A | |
| 3/24/2011 | | ($0.19) | ($0.08) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Coherus BioSciences (NASDAQ:CHRS)Current Year EPS Consensus Estimate: $-4.39 EPS
Next Year EPS Consensus Estimate: $-3.07 EPS
Dividend History for Coherus BioSciences (NASDAQ:CHRS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Coherus BioSciences (NASDAQ:CHRS)Insider Ownership Percentage: 32.88%
Institutional Ownership Percentage: 73.37%
Insider Trades by Quarter for Coherus BioSciences (NASDAQ:CHRS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/5/2017 | Alan C Herman | Insider | Sell | 600 | $15.00 | $9,000.00 | |
| 4/3/2017 | Alan C Herman | Insider | Sell | 11,333 | $20.73 | $234,933.09 | |
| 1/25/2017 | Jean-Frederic Viret | CFO | Sell | 3,900 | $27.00 | $105,300.00 | |
| 12/16/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $28.30 | $110,370.00 | |
| 12/8/2016 | Mats Wahlstrom | Director | Sell | 53,583 | $27.52 | $1,474,604.16 | |
| 12/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $27.40 | $310,524.20 | |
| 10/21/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $30.62 | $119,418.00 | |
| 10/3/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.69 | $291,144.77 | |
| 9/26/2016 | Jean-Frederic Viret | CFO | Sell | 3,900 | $29.88 | $116,532.00 | |
| 9/21/2016 | Dennis M Lanfear | Insider | Sell | 4,060 | $31.75 | $128,905.00 | |
| 9/16/2016 | Dennis M Lanfear | Insider | Sell | 2,900 | $31.79 | $92,191.00 | |
| 8/8/2016 | Fmr Llc | Insider | Sell | 100,000 | $29.86 | $2,986,000.00 | |
| 8/5/2016 | Fmr Llc | Insider | Sell | 48,600 | $28.48 | $1,384,128.00 | |
| 8/1/2016 | Alan C Herman | Insider | Sell | 11,333 | $25.54 | $289,444.82 | |
| 7/21/2016 | Peter K Watler | Insider | Sell | 3,991 | $26.13 | $104,284.83 | |
| 7/20/2016 | Peter K Watler | Insider | Sell | 73,741 | $25.02 | $1,844,999.82 | |
| 7/11/2016 | Peter K Watler | Insider | Sell | 43,495 | $20.02 | $870,769.90 | |
| 7/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $16.89 | $71,782.50 | |
| 6/1/2016 | Alan C Herman | Insider | Sell | 4,250 | $18.67 | $79,347.50 | |
| 5/17/2016 | Peter K Watler | Insider | Sell | 12,000 | $20.00 | $240,000.00 | |
| 5/2/2016 | Alan C Herman | Insider | Sell | 4,250 | $19.20 | $81,600.00 | |
| 2/5/2016 | Alan C Herman | Insider | Sell | 2,000 | $15.02 | $30,040.00 | |
| 12/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $29.49 | $334,210.17 | |
| 11/13/2015 | Christos Richards | Director | Sell | 15,000 | $27.49 | $412,350.00 | |
| 11/2/2015 | Alan C. Herman | insider | Sell | 18,416 | $28.71 | $528,723.36 | |
| 10/1/2015 | Alan C. Herman | insider | Sell | 4,250 | $18.98 | $80,665.00 | |
| 9/1/2015 | Alan C. Herman | insider | Sell | 11,333 | $27.39 | $310,410.87 | |
| 8/18/2015 | Mats Wahlstrom | Director | Sell | 6,373 | $33.50 | $213,495.50 | |
| 8/17/2015 | Mats Wahlstrom | Director | Sell | 8,028 | $33.91 | $272,229.48 | |
| 8/14/2015 | Mats Wahlstrom | Director | Sell | 116,554 | $34.24 | $3,990,808.96 | |
| 6/15/2015 | August J Troendle | Director | Sell | 250,000 | $26.68 | $6,670,000.00 | |
| 11/12/2014 | Eli & Co Lilly | Insider | Buy | 164,963 | $13.50 | $2,227,000.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Coherus BioSciences (NASDAQ:CHRS)
Latest Headlines for Coherus BioSciences (NASDAQ:CHRS)
| Source: |
|
| Date | Headline |
|---|
 | Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - July 4 at 1:08 PM |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - July 3 at 2:28 PM |
 | Coherus BioSciences (CHRS) Reduces Workforce by 51 Employees - StreetInsider.com
www.streetinsider.com - June 28 at 2:34 AM |
| Coherus BioSciences (CHRS) Reduces Workforce by 51 Employees
www.streetinsider.com - June 27 at 9:32 PM |
| Coherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor
www.streetinsider.com - June 27 at 4:31 PM |
| Coherus BioSciences (CHRS) Reports Alternative Fill-Finish Vendor - StreetInsider.com
www.streetinsider.com - June 26 at 5:00 PM |
 | Coherus BioSciences Receives Complete Response Letter from FDA for its Biologics License Application for CHS-1701 (Pegfilgrastim Biosimilar Candidate)
finance.yahoo.com - June 21 at 3:13 AM |
| Coherus BioSciences, Inc. (CHRS) Earns Outperform Rating from Credit Suisse Group
www.americanbankingnews.com - June 14 at 5:20 PM |
| Coherus BioSciences, Inc. (CHRS) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - June 13 at 4:04 PM |
 | Coherus Biosciences Inc. (CHRS) Is Sinking After FDA Complete Response Letter
www.nasdaq.com - June 13 at 3:51 PM |
 | Coherus Biosciences Inc. (CHRS) Sank To An 11-Month Low On FDA News
www.rttnews.com - June 13 at 3:51 PM |
| ETFs with exposure to Coherus BioSciences, Inc. : June 12, 2017
finance.yahoo.com - June 13 at 3:51 PM |
 | Biotech Movers: Acceleron, Clovis, Coherus - TheStreet.com
www.thestreet.com - June 13 at 3:51 PM |
| Coherus BioSciences' (CHRS) "Buy" Rating Reiterated at J P Morgan Chase & Co
www.americanbankingnews.com - June 13 at 2:44 PM |
| Coherus BioSciences, Inc. (CHRS) Given a $38.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - June 13 at 2:44 PM |
| Coherus BioSciences, Inc. (CHRS) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - June 13 at 12:52 PM |
| Mid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge - Nasdaq
www.nasdaq.com - June 13 at 12:41 PM |
 | Why Coherus Biosciences Shares Are Crashing - 24/7 Wall St.
247wallst.com - June 13 at 12:41 PM |
| Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : June 13, 2017
finance.yahoo.com - June 13 at 12:41 PM |
| Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar
finance.yahoo.com - June 13 at 12:41 PM |
| Coherus Biosciences Inc (CHRS) Hits ‘Speed Bump’ for CHS-1701; Maxim Remains Positive
finance.yahoo.com - June 13 at 12:41 PM |
| Coherus BioSciences' (CHRS) "Outperform" Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - June 13 at 10:58 AM |
| Coherus BioSciences' (CHRS) "Outperform" Rating Reiterated at Robert W. Baird
www.americanbankingnews.com - June 13 at 10:58 AM |
| BMO Capital Markets Reaffirms "Outperform" Rating for Coherus BioSciences, Inc. (CHRS)
www.americanbankingnews.com - June 13 at 10:58 AM |
 | Mid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge - Benzinga
www.benzinga.com - June 12 at 5:18 PM |
| Why Pandora Media, Coherus Biosciences, and Erin Energy Slumped Today
finance.yahoo.com - June 12 at 5:18 PM |
| Coherus BioSciences' (CHRS) "Buy" Rating Reaffirmed at Maxim Group
www.americanbankingnews.com - June 12 at 4:20 PM |
| Coherus BioSciences, Inc. :CHRS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017
finance.yahoo.com - June 9 at 4:54 PM |
| Coherus Biosciences Inc (CHRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 9 at 2:38 PM |
| -$1.40 Earnings Per Share Expected for Coherus Biosciences Inc (CHRS) This Quarter
www.americanbankingnews.com - June 7 at 12:20 PM |
| Implied Volatility Surging for Coherus Biosciences (CHRS) Stock Options - Nasdaq
www.nasdaq.com - June 5 at 4:13 PM |
| Implied Volatility Surging for Coherus Biosciences (CHRS) Stock Options
finance.yahoo.com - June 5 at 12:18 PM |
| Coherus Biosciences Inc (CHRS) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - June 4 at 11:10 PM |
| Coherus BioSciences, Inc. breached its 50 day moving average in a Bearish Manner : CHRS-US : June 1, 2017
finance.yahoo.com - June 1 at 4:52 PM |
| Coherus BioSciences Management to Present at 36th NASDAQ OMX Investor Program
finance.yahoo.com - June 1 at 4:52 PM |
| Coherus Biosciences Inc (CHRS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 26 at 9:24 PM |
| Coherus Biosciences Inc (CHRS) Stock Rating Reaffirmed by Barclays PLC
www.americanbankingnews.com - May 21 at 9:28 AM |
| Coherus BioSciences Inc. (CHRS) Leaped After Patent Victory
www.rttnews.com - May 18 at 11:13 AM |
| AbbVie Down on Humira Patent Loss: Is More Damage in Store?
finance.yahoo.com - May 18 at 11:13 AM |
| Coherus Biosciences Inc (CHRS) Given a $38.00 Price Target at Citigroup Inc
www.americanbankingnews.com - May 17 at 8:32 PM |
| Coherus BioSciences Prevails in '135 IPR Decision - NASDAQ.com - Nasdaq
www.nasdaq.com - May 17 at 4:23 PM |
| AbbVie Stock Lower on Humira Patent Ruling
finance.yahoo.com - May 17 at 11:38 AM |
| Coherus Biosciences Inc (CHRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 15 at 1:08 PM |
| Coherus Biosciences Inc (CHRS) Receives "Buy" Rating from Maxim Group
www.americanbankingnews.com - May 15 at 10:14 AM |
| Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock? - Nasdaq
www.nasdaq.com - May 12 at 10:04 PM |
| Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : May 12, 2017
finance.yahoo.com - May 12 at 10:04 PM |
| Are Options Traders Betting on a Big Move in COHERUS BIOSCIENCES (CHRS) Stock?
finance.yahoo.com - May 12 at 4:51 PM |
| Coherus BioSciences, Inc. breached its 50 day moving average in a Bullish Manner : CHRS-US : May 11, 2017
finance.yahoo.com - May 11 at 4:56 PM |
| Coherus Biosciences Inc (CHRS) Expected to Post Earnings of -$1.40 Per Share
www.americanbankingnews.com - May 11 at 4:23 PM |
| Maxim Group Analysts Give Coherus Biosciences Inc (CHRS) a $43.00 Price Target
www.americanbankingnews.com - May 10 at 12:16 AM |
Coherus BioSciences (CHRS) Chart for Friday, July, 21, 2017
